Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam

No Clinical Safety or Efficacy Issues Identified

No Requirement for Further Clinical Data or Trials

See more here


New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection

Cefepime-Taniborbactam Superior to Meropenem for the Composite Efficacy Endpoint

Composite Efficacy Sustained at Late Follow-up Visit

Safety Profile Consistent with Meropenem

See more here


Unite Us and Ride Health Partner to Improve Access to Transportation Services for New Yorkers

The Collaborative Initiative with Social Care Networks Will Overcome Obstacles to Vital Services Following New York State’s Approval of the 1115 Medicaid Waiver

See more here


Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile

See more here


“Sean Lyden MD, Professor and Chairman Vascular Surgery Cleveland Clinic on the mainstage at ISET 2024”

See more here


SIRPant Immunotherapeutics Strengthens Board of Directors with Appointment of Roger Sawhney, M.D.

See more here


Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries

See more here


Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025

Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs

Zentalis to receive up-front payment of $35 million in cash and Immunome common stock and is eligible to receive up to $275 million of milestone payments and mid-to-high single-digit royalties

See more here